title: Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.
abstract: BACKGROUND
  Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels.
  
  
  OBJECTIVE
  LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs.
  
  
  METHODS
  Thirty-eight client-owned animals diagnosed with multicentric lymphoma.
  
  
  METHODS
  Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy.
  
  
  RESULTS
  The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%.
  
  
  CONCLUSIONS
  Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.
authors.affiliation: Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA. luried@vetmed.ufl.edu
authors.forename: D M
authors.initials: DM
authors.lastname: Lurie
authors.forename: I K
authors.initials: IK
authors.lastname: Gordon
authors.forename: A P
authors.initials: AP
authors.lastname: Théon
authors.forename: C O
authors.initials: CO
authors.lastname: Rodriguez
authors.forename: S E
authors.initials: SE
authors.lastname: Suter
authors.forename: M S
authors.initials: MS
authors.lastname: Kent
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006400:Hematocrit / Q000662:veterinary; D017619:Hemibody Irradiation / Q000379:methods / Q000662:veterinary; D016130:Immunophenotyping / Q000662:veterinary; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000662:veterinary*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone